JMI LABS IS NOW PART OF LEARN MORE

Activity of cefiderocol against carbapenem non-susceptible <i>Pseudomonas aeruginosa</i>, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022).  Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain

Poster #MTV0605

View Poster